A patient receives a nasal spray vaccine.Photo:TIM SLOAN/AFP via Getty
TIM SLOAN/AFP via Getty
The Food and Drug Administration (FDA)is reviewing an at-home vaccine for the 2024-25flu season.
Earlier this week, AstraZenecaannouncedthat the FDA is reviewing an application for its nasal spray flu vaccine FluMist, which would become the first self-administered flu vaccine available across the United States, should it be approved.
FluMist would be available to be shipped to users' homes in temperature-controlled packaging, AstraZeneca’s Dr. Lisa Glasser toldCNN. It could still, however, also be administered at a doctor’s office or pharmacy as well, the outlet said.
Never miss a story — sign up forPEOPLE’s free daily newsletterto stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories.
Pharmacy worker holds nasal spray doses of the flu vaccine.Mario Tama/Getty
Mario Tama/Getty
The study, the outlet said, also determined that about 43 percent of adults do not plan to or are unsure if they will get vaccinated against the flu between 2023 and 2024.
40 percent, meanwhile, said they plan to get vaccinated against COVID-19, while only 40 percent of adults aged 60 years and older said they plan to get vaccinated against RSV.
Last month, Mandy Cohen, who is the Centers for Disease Control and Prevention (CDC) director, said that only 47 percent of adults in the U.S. received a vaccine during the 2022-23 flu season, The Hill reported.
That number was down from the previous 2021-22 season, which saw 49 percent of U.S. adults get vaccinated, the outlet said.
source: people.com
